Informazioni sulla sperimentazione dei farmaci

Cerca "Vai

Codice EUDRACT	Titolo/oggetto del contratto di sperimentazione	Promotore
Visualizza # Pagina 1 di 14 Totale: 329 Inizia Prev 1 2 3 4 5 6 7 8 9 10 Successivo Fine
Non ci sono record
2016-002154-20	A multicenter, randomized, double-bind, active-controlled, parallelgroup Phase 3 study to evaluate the efficacy and safety of LCZ696 compared to ramipril ...	Novartis Farma S.p.A per Novartis Pharma AG	Dettaglio
2015-001564-19	A multicenter, randomized, open-label Phase 2 study evaluating the safety and efficacy of three different regimens of oral panobinostat in ...	Novartis Farma S.p.A per Novartis Pharma AG	Dettaglio
2019-001545-41	A Phase 1/2A First in Human Study of the Menin-MLL (KMT2A) Inhibitor KO-539 in Patients with Relapsed or Refractory Acute ...	Kura Oncology, Inc.	Dettaglio
2019-004948-30	A Phase 2, Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants With Advanced Malignancies Previously Enrolled in Studies ...	Incyte Corporation	Dettaglio
2015-003447-19	A phase 3 Multicenter Open-label Study of Brigatinib (AP26113) versus Crizotinib in Patients with ALK-positive Advanced Lung Cancer	ARIAD Pharmaceuticals Inc. un’azienda interamente controllata da Takeda Pharmaceutical Company Limited	Dettaglio
2021-001234-20	A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) versus Bendamustine plus Rituximab in Untreated Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma ...	Loxo Oncology, Inc. 281 Tresser Boulevard Stamford, CT 06901	Dettaglio
2020-000241-14	A Phase 3 Randomized Study of Loncastuximab Tesirine Combined with Rituximab Versus Immunochemotherapy in Patients with Relapsed or Refractory Diffuse ...	ADC Therapeutics SA	Dettaglio
2017-000996-98	A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects with ...	CSL Behring LLC	Dettaglio
2021-001825-33	A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in ...	Janssen-Cilag SpA	Dettaglio
2019-003126-25	A Phase I/II, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Efficacy of ZD9008 in Patients with ...	Dizal (Jiangsu) Pharmaceutical Co., Ltd	Dettaglio
2015-001998-40	A phase Ib/II study evaluating the safety and efficacy of obinutuzumab in combination with polatuzumab vedotin and venetoclax in patients ...	F.Hoffmann-La Roche Ltd	Dettaglio
2016-003703-62	A phase II study of metronomic chemotherapy in elderly non-fit patients (>65 years) with aggressive B-Cell lymphomas	Fondazione Italiana Linfomi ONLUS (FIL)	Dettaglio
2016-004359-57	A Phase III Study of BBI-608 plus nab-Paclitaxel whit Gemcitabine in Adult Patients with Metastatic Pancreatic Adenocarcinoma	Boston Biomedical Inc	Dettaglio
2017-004011-39	A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant ...	Novartis Farma S.p.A per Novartis Pharma AG	Dettaglio
2017-001664-37	A randomized phase 2 study comparing immunotherapy with chemotherapy in the treatment of elderly patients with advanced NSCLC	Istituto Nazionale per la Cura dei Tumori-Fondazione G.Pascale	Dettaglio
2015-001151-68	A randomized Phase III study to compare arsenic trioxide (ATO) combined to ATRA and idarubicin versus standard ATRA and anthracycLine-based ...	Università di Dresda	Dettaglio
2018-000367-83	A Randomized Phase III Trial of Platinum Chemotherapy plus Paclitaxel with Bevacizumab and Atezolizumab versus Platinum Chemotherapy plus Paclitaxel and ...	GEICO	Dettaglio
2016-003726-17	A Randomized, Open-Label, Multicenter, Phase 3 Study of Rovalpituzumab Tesirine Compared with Topotecan for Subjects with Advanced or Metastatic DLL3high ...	AbbVie S.r.l.	Dettaglio
2016-002509-21	A randomized, open-label, multicenter, phase III, 2-arm study comparing efficacy and tolerability of the intensified variant ‘dose-dense/dose-intense ABVD’ (ABVD DD-DI) ...	Fondazione Italiana Linfomi ONLUS (FIL)	Dettaglio
2020-000547-31	An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients with B-cell Malignancies	BeiGene, Ltd sede Isole Cayman	Dettaglio
2017-000981-31	Atezolizumab, Pertuzumab e Trastuzumab in combinazione con chemioterapia come terapia neoadiuvante in pazienti con tumore mammario HER2 positivo in stadio ...	Fondazione Michelangelo Onlus	Dettaglio
2018-000877-61	Attività e sicurezza dell’associazione di Venetoclax e Rituximab (VeRiTAs) in prima linea in pazienti giovani e fit con leucemia linfatica cronica ...	Fondazione GIMEMA Franco Mandelli Onlus	Dettaglio
2018-000635-27	Brigatinib in pazienti con carcinoma polmonare non a piccole cellule (NSCLC) in stadio avanzato , positivo per la chinasi del ...	ARIAD Pharmaceuticals Inc. un’azienda interamente controllata da Takeda Pharmaceutical Company Limited	Dettaglio
2018-000540-25	Carfilzomib (K) in combinazione con Lenalidomide (R) e Desametasone (D) come terapia di salvataggio per linfomi mantellari ricaduti,refrattari ...	Fondazione Italiana Linfomi ONLUS (FIL)	Dettaglio
2018-002068-15	CARFILZOMIB - LENALIDOMIDE - DEXAMETHASONE (KRd) versus LENALIDOMIDE - DEXAMETHASONE (Rd) IN NEWLY DIAGNOSED MYELOMA PATIENTS NOT ELIGIBLE FOR AUTOLOGOUS ...	FO.NE.SA. Onlus	Dettaglio

Cerca:	Pulisci
Titolo/oggetto del contratto di sperimentazione
Codice EUDRACT
Promotore
Nome Unità Operativa
Principal investigator

W06 Informazioni sulle sperimentazioni dei farmaci (art.11, c.4bis, D.Lgs 211/200)